Knowledge Hub

Metabotropic Glutamate Receptor Market By Analysis, Pricing, Type And Shares, Forecast To 2017

Press Release   •   Aug 30, 2017 06:11 EDT

About  Metabotropic Glutamate Receptor Market

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 12 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Musculoskeletal Disorders which include indications Dyskinesia, Anxiety Disorders, Autism, Depression, Schizophrenia, Cognitive Impairment Associated With Schizophrenia (CIAS), Major Depressive Disorder, Alcohol Addiction, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Chronic Pain, Cognitive Disorders, Cognitive Impairment, DiGeorge Syndrome, Fragile X Syndrome, Generalized Anxiety Disorder (GAD), Mania, Neurology, Opium (Opioid) Addiction, Pain, Parkinson's Disease, Spasmodic Torticollis and Substance (Drug) Abuse.

The latest report Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2017, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)

- The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects

- The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1305499

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview 8

View Sample PDF @ https://www.marketresearchreports.biz/reports/1305499/metabotropic-glutamate-receptor-5-gprc1e-or-mglur5-or-grm5-pipeline-review-h2-2017-market-research-reports.pdf

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment 19

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 22

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development 23

Addex Therapeutics Ltd 23

Aevi Genomic Medicine Inc 23

Bristol-Myers Squibb Company 24

Eisai Co Ltd 24

Eli Lilly and Company 25

Heptares Therapeutics Ltd 25

Johnson & Johnson 26

Merz Pharma GmbH & Co KgaA 26

Novartis AG 27

Richter Gedeon Nyrt 27

Sumitomo Dainippon Pharma Co Ltd 28

Toray Industries Inc 28

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles 29

alloswitch-1 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

BMS-952048 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

BMS-955829 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

dipraglurant ER - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

dipraglurant IR - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

DSR-98776 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

fasoracetam - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

GET-73 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

HTL-14242 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

JNJ-46778212 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

LSN-2814617 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

mavoglurant - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

PAM-12 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1305499

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz